Thomas Cable Biography and Net Worth

Director of Omeros

Thomas J. Cable has served on our board of directors since January 1995 and as our Lead Independent Director since 2010. Mr Cable is the vice chairman of the board of the Washington Research Foundation, a technology transfer and early-stage venture capital organization affiliated with the University of Washington, which he cofounded in 1980. He also founded Cable & Howse Ventures, a venture capital firm, and Cable, Howse & Ragen, an investment banking firm, and co-founded Montgomery Securities, an investment banking firm acquired by Bank of America. A former US Navy submarine officer, Mr Cable received his MBA from the Stanford Graduate School of Business and his BA from Harvard University.

What is Thomas J. Cable's net worth?: The estimated net worth of Thomas J. Cable is at least $306.13 thousand as of May 22nd, 2026. Cable owns 35,067 shares of Omeros stock worth more than $306,135 as of June 14th. This net worth approximation does not reflect any other investments that Cable may own. Learn More about Thomas J. Cable's net worth.
How do I contact Thomas J. Cable?: The corporate mailing address for Cable and other Omeros executives is 201 ELLIOT AVENUE WEST, SEATTLE WA, 98119. Omeros can also be reached via phone at (206) 676-5000 and via email at [email protected]. Learn More on Thomas J. Cable's contact information.
Has Thomas J. Cable been buying or selling shares of Omeros?: During the last quarter, Thomas J. Cable has sold $87,075.00 of Omeros stock. Most recently, Thomas J. Cable sold 7,500 shares of the business's stock in a transaction on Friday, May 22nd. The shares were sold at an average price of $11.61, for a transaction totalling $87,075.00. Following the completion of the sale, the director now directly owns 35,067 shares of the company's stock, valued at $407,127.87. Learn More on Thomas J. Cable's trading history.
Who are Omeros' active insiders?: Omeros' insider roster includes David Borges (CAO), Thomas Cable (Director), Gregory Demopulos (CEO), Peter Demopulos (Director), and Michael Jacobsen (CAO). Learn More on Omeros' active insiders.
Are insiders buying or selling shares of Omeros?: During the last year, insiders at the biopharmaceutical company sold shares 2 times. They sold a total of 37,500 shares worth more than $456,375.00. The most recent insider tranaction occured on May, 22nd when Director Thomas J Cable sold 7,500 shares worth more than $87,075.00. Insiders at Omeros own 12.9% of the company. Learn More about insider trades at Omeros.
Information on this page was last updated on 5/22/2026.

Thomas J. Cable Insider Trading History at Omeros

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/22/2026	Sell	7,500	$11.61	$87,075.00	35,067
1/13/2021	Sell	5,000	$16.97	$84,850.00	40,067
5/13/2020	Sell	5,000	$14.40	$72,000.00	40,067
12/3/2019	Sell	10,000	$13.16	$131,600.00
10/14/2019	Sell	5,000	$15.12	$75,600.00	35,067
4/12/2017	Sell	3,000	$16.49	$49,470.00	40,067
3/24/2016	Sell	2,000	$14.81	$29,620.00	49,467
7/15/2015	Sell	2,000	$18.78	$37,560.00
3/24/2015	Sell	2,000	$24.50	$49,000.00
6/2/2014	Sell	5,000	$11.80	$59,000.00
7/3/2013	Sell	5,000	$5.21	$26,050.00
4/10/2013	Sell	5,000	$3.98	$19,900.00

Thomas J. Cable Buying and Selling Activity at Omeros

Omeros Company Overview

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

Today's Range

Now: $8.73

$6.70

$10.11

50 Day Range

MA: $12.18

$8.73

$14.83

2 Week Range

Now: $8.73

$2.95

$17.65

Volume

7,780,719 shs

Average Volume

1,912,292 shs

Market Capitalization

$631.88 million

P/E Ratio

12.47

Dividend Yield

N/A

Beta

2.52